MICROBIOCENOSIS DISORDERS PROVOKE OXIDATIVE STRESS AS A SIGNIFICANT PATHOGENETIC FACTOR IN NON-ALCOHOLIC STEATOHEPATITIS COMBINED WITH ISCHEMIC HEART DISEASE

Authors:

Abstract:

The study presents the results of our own research evaluating the impact of intestinal microbiocenosis disorders on oxidative stress activity and the degree of dyslipidemia in patients with combined non-alcoholic fatty liver disease and ischemic heart disease. The study included 44 patients with non-alcoholic steatohepatitis and concurrent ischemic heart disease. Patients were divided into two groups based on the presence of intestinal microbiocenosis disruptions. The findings demonstrate that under these comorbid conditions, microbiocenosis disturbances are characterized by: reduced lactobacilli counts in 95 % of patients, decreased bifidobacteria levels in 90.9 %, lower total Escherichia coli counts in 50 % of patients. A decrease in the total amount of Escherichia coli is associated with the emergence of opportunistic microflora. Under conditions combining non-alcoholic steatohepatitis and ischemic heart disease, impaired gut microbiota composition exacerbates the severity of dyslipidemia and triggers the production of reactive oxygen species with depletion of antioxidant defense enzymes. This is characterized by an increase in thiobarbituric acid-reactive substances (TBARS/TBA-reactants) levels alongside a simultaneous decrease in superoxide dismutase activity compared to normal gut microbiota composition.

Keywords:

non-alcoholic steatohepatitis ischemic heart disease gut microbiota (microbiocenosis) oxidative stress antioxidant defense dyslipidemia

References:

1. Skrypnyk IM, Shcherbak OV, Maslova HS. Vplyv nealkoholnoho steatohepatytu na kharakter perebihu ta prohresuvannya ishemichnoyi khvoroby sertsya. Wiadomości Lekarskie. 2017; LXX. nr 2 (cz. I):236-40.
2. Baratta F, Pastori D, Angelico F, Balla A, Paganini AM, Cocomello N, et al. Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study. Clin Gastroenterol Hepatol. 2020 Sep;18(10):2324-2331.e4. doi: 10.1016/j.cgh.2019.12.026.
3. Chung GE, Cho EJ, Yoo JJ, Chang Y, Cho Y, Park SH, et al. Young adults with nonalcoholic fatty liver disease, defined using the fatty liver index, can be at increased risk of myocardial infarction or stroke. Diabetes Obes Metab. 2022 Mar;24(3):465-472. doi: 10.1111/dom.14597.
4. Fadieienko GD, Gridnyev OY, Kushnir IE. Nonalcoholic fatty liver disease and cardiovascular risk. Ukrain. Therap. J, 2024, pp. 66-76.
5. Labenz C, Huber Y, Michel M, Nagel M, Galle PR, Kostev K, et al. Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany. Dig Dis Sci. 2020 Jul;65(7):2112-2119. doi: 10.1007/s10620-019-05986-9.
6. Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, et al. NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022 Jan;19(1):60-78. doi: 10.1038/s41575-021-00523-4.
7. Lee KC, Wu PS, Lin HC. Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis. Clin Mol Hepatol. 2023 Jan;29(1):77-98. doi: 10.3350/cmh.2022.0237.
8. Lee SR, Han KD, Choi EK, Oh S, Lip GYH. Nonalcoholic fatty liver disease and the risk of atrial fibrillation stratified by body mass index: a nationwide population-based study. Sci Rep. 2021 Feb 12;11(1):3737. doi: 10.1038/s41598-021-83367-x.
9. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021 Jun 5;397(10290):2212-2224. doi: 10.1016/S0140-6736(20)32511-3.
10. Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019 Apr;7(4):313-324. doi: 10.1016/S2213-8587(18)30154-2.
11. Tang WH, Kitai T, Hazen SL. Gut Microbiota in Cardiovascular Health and Disease. Circ Res. 2017 Mar 31;120(7):1183-1196. doi: 10.1161/CIRCRESAHA.117.309715.
12. Yang YJ, Jung MH, Jeong SH, Hong YP, Kim YI, An SJ. The Association between Nonalcoholic Fatty Liver Disease and Stroke: Results from the Korean Genome and Epidemiology Study (KoGES). Int J Environ Res Public Health. 2020 Dec 21;17(24):9568. doi: 10.3390/ijerph17249568.
13. Wu M, Zha M, Lv Q, Xie Y, Yuan K, Zhang X, et al. Non-alcoholic fatty liver disease and stroke: A Mendelian randomization study. Eur J Neurol. 2022 May;29(5):1534-1537. doi: 10.1111/ene.15277.

Publication:

«World of Medicine and Biology» Vol. 21 No. 91 (2025) , с. 101-105
УДК 616.12-005.4: 616.36-002: 612.08

DOI:

https://doi.org/10.26724/2079-8334-2025-1-91-101-105